Men diagnosed with high-risk localized prostate cancer now have trial-level evidence that adding the drug apalutamide to ...

A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...

PROTEUS results reshape high‑risk localized prostate cancer care, adding apalutamide plus androgen deprivation before surgery as a new option. The phase 3 PROTEUS trial data may add a new ...

Johnson & Johnson (JNJ) reported late-stage clinical trial results showing that adding its prostate cancer drug apalutamide to hormone therapy before and after surgery improved outcomes for men with ...

At a median follow-up of 21.5 months, ADT plus apalutamide significantly prolonged median PSA progression-free survival compared with ADT monotherapy (24.9 vs 20.3 months; hazard ratio [HR], 0.52).

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The next-generation oral antiandrogen product apalutamide (Erleada, Janssen), is approaching approval in Europe for use in nonmetastatic castration-resistant prostate cancer (nmCRPC). The product ...

Measuring oncological value of exercise and statin: Can we improve the prognosis of patients with cancer and change the microenvironment in different tumor types with exercise and statins (MOVES study ...

Post hoc analysis of rPFS and OS from the TALAPRO-2 (TP-2) study: Genomic subgroups based on likelihood of BRCA or HRR gene alteration status. This is an ASCO Meeting Abstract from the 2024 ASCO ...

Practice-changing perioperative therapy, chemo-free combo for CSPC, reducing cognitive eff ...

After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death. An updated analysis of patients in the SPARTAN ...